IVD Medical, Transcenta to tokenize drug pipelines in $1.5 bn RWA deal

IVD Medical Holding Limited, through its subsidiaries ETHK Inc and ETHK Holdings Limited, has signed a strategic cooperation agreement with Transcenta Holding Limited and its subsidiary Transcenta Oncology Inc. (US). This partnership focuses on the Real World Asset (RWA) Tokenization of six core innovative drug pipelines, including TST003, TST005, TST786, TST105, TST106, and TST013. These assets are valued at over US$1.5 billion and will be consolidated under Transcenta Oncology Inc. (US).

The collaboration leverages IVD’s ETHK Global Innovative Drug Intellectual Property RWA Exchange to provide technical solutions for digital origination, trusted on-chain processing, compliant issuance, and liquidity integration of these assets. This initiative marks the first time high-value innovative drug intellectual property assets are being launched in capital markets as RWA, aiming to advance R&D financing and value realization in the biopharmaceutical industry without diluting equity.

A signing ceremony is scheduled for Monday, 22 September 2025, in Nanjing. Shareholders and potential investors are reminded that the strategic cooperation agreement outlines intentions and is not legally binding, with further announcements to be made upon the agreement of a formal, legally binding document.